Christian Schade
Chairman bij OMEGA THERAPEUTICS, INC.
Vermogen: 2 M $ op 31-03-2024
Profiel
Christian S.
Schade is currently the President, Chief Executive Officer & Director at Aprea Therapeutics AB since 2016.
He is also the Chairman at Princeton Academy of the Sacred Heart since 2009, Chairman at Sapience Therapeutics, Inc., Chairman at Omega Therapeutics, Inc. since 2023, Independent Director at Integra LifeSciences Holdings Corp.
since 2006, and Growth Partner at Flagship Pioneering since 2023.
Previously, Mr. Schade served as the Chief Executive Officer & Director at Novira Therapeutics LLC from 2014 to 2015.
He was also the Chairman at Aprea Therapeutics, Inc. from 2016 to 2023.
Additionally, he held positions such as Managing Director at Merrill Lynch International, Independent Non-Executive Director at Indivior PLC from 2014 to 2019, Chief Financial Officer & Senior VP-Administration at Medarex, Inc. from 2000 to 2009, Chief Financial Officer & Executive Vice President at NRG Energy, Inc. from 2010 to 2011, Principal at JPMorgan Chase & Co., and Chief Financial Officer & Executive Vice President at Omthera Pharmaceuticals, Inc. from 2011 to 2013.
Mr. Schade completed his undergraduate studies at Princeton University and holds an MBA from The Wharton School of the University of Pennsylvania.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
29-02-2024 | 54 807 ( 0.07% ) | 2 M $ | 31-03-2024 | |
APREA THERAPEUTICS, INC.
0.22% | 26-06-2023 | 11 892 ( 0.22% ) | 79 557 $ | 31-03-2024 |
OMEGA THERAPEUTICS, INC.
-.--% | 07-02-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Christian Schade
Bedrijven | Functie | Begin |
---|---|---|
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Director/Board Member | 01-01-2006 |
OMEGA THERAPEUTICS, INC. | Chairman | 29-08-2023 |
Princeton Academy of the Sacred Heart | Chairman | 01-07-2009 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Chief Executive Officer | 01-04-2016 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | Chairman | - |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 31-01-2023 |
Eerdere bekende functies van Christian Schade
Bedrijven | Functie | Einde |
---|---|---|
APREA THERAPEUTICS, INC. | Chief Executive Officer | 29-06-2022 |
INDIVIOR PLC | Director/Board Member | 31-07-2019 |
Novira Therapeutics LLC
Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Chief Executive Officer | 01-12-2015 |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Christian Schade
Princeton University | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 6 |
---|---|
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Health Technology |
NRG ENERGY, INC | Utilities |
JPMORGAN CHASE & CO. | Finance |
INDIVIOR PLC | Health Technology |
OMEGA THERAPEUTICS, INC. | Health Technology |
APREA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 8 |
---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
Merrill Lynch International
Merrill Lynch International Investment Banks/BrokersFinance Merrill Lynch International (MLI-UK) is a brokerage firm headquartered in London, UK. The firm was founded in 1988 and is a subsidiary of ML UK Capital Holdings Ltd., ultimately owned by Bank of America Corp. (NYSE: BAC) in the US. MLI-UK provides brokerage services to individual and retail clients. | Finance |
Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Health Technology |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Princeton Academy of the Sacred Heart | |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | Health Technology |
Novira Therapeutics LLC
Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Health Technology |